Report of Foreign Issuer (6-k)
December 26 2018 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of December 2018
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On December 25,
2018, Chaim Hurwitz resigned as Chairman of the Board of Directors (“Board”) of Galmed Pharmaceuticals Ltd. (the
“Company”), effective immediately, to pursue other opportunities. On December 26, 2018, the Board appointed Allen
Baharaff, the Company’s Chief Executive Officer and current member of the Board, to assume the role of Chairman,
subject to and commencing upon shareholder approval. Additionally, the Board appointed David Sidransky, M.D., an external
director of the Company and chair of the Nominating Committee, to assume the newly created role as Lead Independent Director,
effective immediately. In the newly created role of Lead Independent Director, Dr. Sidransky will preside at executive
sessions of the Board, serve as a liaison between the Chairman and the independent directors, and approve matters to be
considered by the Board in meeting agendas. The Lead Independent Director will also provide leadership to the Board if
circumstances arise in which the role of the Chairman may be, or may be perceived to be, in conflict, and responding to any
reported conflicts of interest, or potential conflicts of interest, arising for any director.
This Form 6-K is incorporated
by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the
Company’s Registration Statement on Form F-3 (Registration No. 333-223923).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
Date: December 26, 2018
|
By:
/s/ Allen Baharaff
Allen Baharaff
President and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024